Your browser is no longer supported. Please, upgrade your browser.
MCRB Seres Therapeutics, Inc. monthly Stock Chart
MCRB [NASD]
Seres Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own10.00% Shs Outstand73.31M Perf Week24.06%
Market Cap357.70M Forward P/E- EPS next Y-0.98 Insider Trans0.00% Shs Float69.09M Perf Month-15.64%
Income-75.80M PEG- EPS next Q-0.26 Inst Own76.90% Short Float11.11% Perf Quarter0.87%
Sales28.90M P/S12.38 EPS this Y48.90% Inst Trans-1.52% Short Ratio10.58 Perf Half Y31.82%
Book/sh-0.89 P/B- EPS next Y-3.20% ROA-64.80% Target Price- Perf Year76.43%
Cash/sh0.83 P/C5.60 EPS next 5Y- ROE145.90% 52W Range2.23 - 6.75 Perf YTD34.49%
Dividend- P/FCF- EPS past 5Y-21.10% ROI303.30% 52W High-31.26% Beta1.04
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low108.07% ATR0.41
Employees108 Current Ratio1.60 Sales Q/Q-52.00% Oper. Margin- RSI (14)54.37 Volatility7.13% 9.21%
OptionableYes Debt/Eq- EPS Q/Q-18.60% Profit Margin- Rel Volume0.95 Prev Close4.43
ShortableYes LT Debt/Eq- EarningsJul 28 BMO Payout- Avg Volume725.29K Price4.64
Recom2.00 SMA207.69% SMA50-0.82% SMA20017.43% Volume689,371 Change4.74%
Apr-30-19Initiated Jefferies Hold $7
Oct-22-18Initiated Chardan Capital Markets Buy $15
Oct-13-17Initiated Oppenheimer Outperform $19
Aug-04-17Reiterated H.C. Wainwright Buy $15 → $19
Feb-01-17Reiterated FBR & Co. Outperform $23 → $18
Aug-12-16Reiterated FBR Capital Outperform $43 → $23
Aug-01-16Reiterated H.C. Wainwright Buy $50 → $15
Aug-01-16Downgrade BofA/Merrill Buy → Neutral
Jul-29-16Resumed H.C. Wainwright Buy $50
Mar-30-16Initiated FBR Capital Outperform $40
Mar-03-16Initiated Guggenheim Buy
Jan-25-16Initiated H.C. Wainwright Buy $55
Oct-22-15Upgrade BofA/Merrill Neutral → Buy
Jul-22-15Initiated Canaccord Genuity Buy $50
Jul-21-15Initiated Leerink Partners Outperform
Jul-21-15Initiated Goldman Neutral
Jul-21-15Initiated BofA/Merrill Neutral
Aug-07-20 08:55AM  
Jul-28-20 12:33PM  
09:41AM  
07:00AM  
Jul-08-20 10:06AM  
Jul-07-20 08:56AM  
08:00AM  
Jun-25-20 11:23AM  
Jun-22-20 07:00AM  
Jun-07-20 06:24PM  
Jun-02-20 04:00PM  
08:36AM  
May-31-20 08:27PM  
May-28-20 08:00AM  
08:00AM  
May-18-20 07:00AM  
May-11-20 02:10AM  
May-09-20 01:31PM  
May-07-20 10:25AM  
07:00AM  
Apr-30-20 12:33PM  
07:00AM  
Apr-06-20 07:00AM  
Mar-30-20 07:00AM  
Mar-23-20 07:00AM  
Mar-19-20 06:56PM  
Mar-15-20 03:00PM  
Mar-13-20 07:00AM  
Mar-04-20 08:56AM  
Mar-02-20 08:15AM  
07:00AM  
Feb-25-20 04:00PM  
07:00AM  
Jan-17-20 08:26AM  
Dec-20-19 05:04PM  
Dec-19-19 08:00AM  
Dec-16-19 07:00AM  
Nov-18-19 12:21PM  
Nov-14-19 07:00AM  
01:55AM  
Nov-05-19 08:35AM  
07:00AM  
Oct-31-19 04:00PM  
Sep-19-19 03:26PM  
Aug-22-19 10:01AM  
Aug-14-19 12:33PM  
Aug-08-19 06:38AM  
Aug-06-19 04:23PM  
08:45AM  
07:00AM  
07:00AM  
06:00AM  
Jul-25-19 10:34AM  
Jun-22-19 09:05AM  
08:59AM  
Jun-19-19 07:00AM  
Jun-17-19 09:37AM  
Jun-13-19 09:23PM  
07:44AM  
Jun-12-19 04:07PM  
May-29-19 04:00PM  
May-08-19 01:29AM  
May-02-19 09:25AM  
08:12AM  
07:00AM  
06:30AM  
Apr-29-19 04:00PM  
Apr-26-19 04:26PM  
Apr-02-19 08:00AM  
Mar-23-19 08:10AM  
Mar-13-19 08:45AM  
Mar-11-19 02:24PM  
01:41PM  
12:58PM  
09:30AM  
Mar-06-19 12:13PM  
07:00AM  
Mar-05-19 04:00PM  
Mar-04-19 07:00AM  
Feb-07-19 09:00AM  
Jan-15-19 07:00AM  
Jan-04-19 02:29PM  
Jan-03-19 07:00AM  
Nov-28-18 08:35AM  
Nov-19-18 11:31PM  
Nov-09-18 07:00AM  
Nov-08-18 09:00AM  
07:00AM  
Nov-05-18 07:00AM  
Oct-22-18 07:00AM  
Oct-18-18 08:15AM  
Oct-16-18 08:12AM  
Oct-03-18 07:00AM  
Aug-24-18 08:10AM  
Aug-14-18 10:07AM  
Aug-03-18 09:14PM  
Aug-02-18 11:10AM  
10:04AM  
07:00AM  
06:30AM  
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chapman MarcusSee RemarksNov 22Sale3.913,40013,2978,600Nov 25 04:32 PM
Chapman MarcusSee RemarksNov 01Option Exercise0.0012,000012,000Nov 25 04:32 PM